Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Enterprise Value (2016 - 2026)

Champions Oncology has reported Enterprise Value over the past 17 years, most recently at -$7.0 million for Q1 2026.

  • Quarterly results put Enterprise Value at -$7.0 million for Q1 2026, down 118.77% from a year ago — trailing twelve months through Jan 2026 was -$7.0 million (down 118.77% YoY), and the annual figure for FY2025 was -$9.8 million, down 273.76%.
  • Enterprise Value for Q1 2026 was -$7.0 million at Champions Oncology, up from -$8.5 million in the prior quarter.
  • Over the last five years, Enterprise Value for CSBR hit a ceiling of -$2.6 million in Q2 2024 and a floor of -$10.8 million in Q4 2022.
  • Median Enterprise Value over the past 5 years was -$6.3 million (2023), compared with a mean of -$6.2 million.
  • Biggest five-year swings in Enterprise Value: surged 49.93% in 2024 and later tumbled 273.76% in 2025.
  • Champions Oncology's Enterprise Value stood at -$10.8 million in 2022, then surged by 49.07% to -$5.5 million in 2023, then soared by 49.93% to -$2.8 million in 2024, then plummeted by 207.01% to -$8.5 million in 2025, then increased by 17.15% to -$7.0 million in 2026.
  • The last three reported values for Enterprise Value were -$7.0 million (Q1 2026), -$8.5 million (Q4 2025), and -$10.3 million (Q3 2025) per Business Quant data.